Gastroparesis-Related Hospitalizations in the United States: Trends, Characteristics, and Outcomes, 1995–2004

Wang, Yize R.; Fisher, Robert S.; Parkman, Henry P.

doi:10.1111/j.1572-0241.2007.01658.x

Cited by 266 publications

(199 citation statements)

References 20 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…Though most patients with diabetic gastroparesis remain asymptomatic, a significant proportion (8-12%) suffers with variable degrees of upper gastrointestinal symptoms that adversely affect their quality of life, glycaemic control and nutritional status [2]. Moreover, some patients may have periods of intractable and debilitating symptoms requiring frequent and prolonged hospital admissions [3]. Acute variations in blood glucose concentration have been found to affect gastric motility in healthy people and patients with diabetes [4,5].…”

Section: Introductionmentioning

confidence: 99%

The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis

et al. 2011

View full text Add to dashboard Cite

Aims/objective To describe the effectiveness of continuous subcutaneous insulin infusion (CSII) in patients with symptomatic diabetic gastroparesis and unstable glycaemic control. Methods Data from 26 patients with symptomatic diabetic gastroparesis and unstable glycaemic control using multiple-dose insulin (MDI) regimens, and subsequently managed with CSII, were analysed. Results Following initiation of CSII, the median length of inpatient bed days associated with hospital admissions related to gastroparesis and glycaemic instability was reduced from 8.5 (range 0-144) days patient −1 year −1 prior to CSII to 0 (range 0-15) days patient −1 year −1 .The median HbA 1c reduction with CSII was 1.8% (22 mmol/mol; p<0.05). The median capillary blood glucose (CBG) with CSII was significantly lower than with MDI: 7.7 mmol/l (range 3.8-15.4 mmol/l) vs 9.8 mmol/l (range 2.3-27 mmol/l), respectively, p<0.001. Glycaemic variability with CSII was significantly reduced compared with MDI: CBG CV 0.37 vs CV 0.53, respectively, p<0.001. Conclusions/interpretation CSII therapy in patients with diabetic gastroparesis results in significant improvement in glycaemic control and reductions in glycaemic variability and number of hospital inpatient bed days.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…уровень заболеваемости гастропарезом в СШа в 1996-2006 гг. составил 2,4 для мужчин и 9,8 для женщин [12,50]. по данным эпидемиологического исследования в Olmsted County (Миннесота, СШа), кумулятивный уровень заболеваемости гастропарезом соcтавил 4,8% для пациентов с Сд 1 типа, 1% для больных Сд 2 типа и 0,1% для пациентов без диабета [16,31].…”

unclassified

Diabetic gastroparesis: epidemiology, mechanisms of development, modern approaches to the management

Tkach¹

2017

CE&ES

View full text Add to dashboard Cite

“…A current rise in interest in the condition, has led to dramatic escalations in its characterization and diagnosis. However, the condition remains unrecognized [11,12]. A clear etiology has not yet been identified nor has its mechanism been quite clarified [13].…”

Section: Introductionmentioning

confidence: 99%

An Analysis of Possible Risk Factors Contributing to Delayed Gastric Emptying after Distal Gastrectomy for Gastric Cancer

Sulav¹,

Shi²,

Ahmad³

et al. 2017

J Gastrointest Dig Syst

View full text Add to dashboard Cite

Gastric cancer is a worldwide epidemic. The standard and definitive treatment for gastric cancer is surgical resection: gastrectomy. Surgery is a common trigger for gastroparesis. DGE is arguably the most common of the post-gastrectomy syndromes, accounting for 5-20% of all cases. A clear etiology still remains unidentified. The purpose of the study is to analyze the possible risk factors contributing to development of DGE after distal gastrectomy for gastric cancer.A retrospective study of 252 patients, who underwent distal gastrectomy for gastric cancer, was conducted from January 2010 to December 2015. 18 patients developed DGE with an occurrence rate of 7.1%. The incidence of DGE was found to be significantly higher in patients with 1) Gastric outlet obstruction (P=0.031), 2) Roux-en-Y reconstruction surgery (P=0.041), 3) Side to end gastrojejunostomy (P=0.03), 4) Tumor in the lower 1/3 rd (P= 0.027) and 5) Ulcerative lesion (P=0.001). DGE continues to affect a considerable number of patients after gastric surgery. Proper preoperative preparation and postoperative management can considerably reduce the incidence of DGE.

show abstract

Gastroparesis-Related Hospitalizations in the United States: Trends, Characteristics, and Outcomes, 1995–2004

Abstract: The number of gastroparesis-related hospitalizations has been increasing in the United States, suggesting an increasing prevalence of gastroparesis. The economic impact of gastroparesis-related hospitalizations is significant and increasing.

Cited by 266 publications

References 20 publications

The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis

The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis

Diabetic gastroparesis: epidemiology, mechanisms of development, modern approaches to the management

An Analysis of Possible Risk Factors Contributing to Delayed Gastric Emptying after Distal Gastrectomy for Gastric Cancer

Contact Info

Product

Resources

About